Market & RegulationInvestment · $200M
OpenAI's Miles Wang plans $2B AI drug startup
TechCrunch AIhigh confidence
Why it matters
- →AI-driven drug discovery could significantly reduce development time and costs.
- →Repurposing existing drugs can lead to faster market entry and revenue generation.
- →The move highlights increasing investor confidence in AI applications within life sciences.
Miles Wang, a researcher from OpenAI, is reportedly planning to launch a new AI-focused drug discovery startup valued at $2 billion. The startup aims to develop AI models that could find new applications for existing drugs, potentially speeding up the drug development process. Wang is in discussions to raise $200 million, with Lightspeed possibly leading the funding round. This move reflects a broader trend of leveraging AI in the life sciences sector, as seen with other companies like Chai Discovery and Isomorphic Labs.
Read originalThe story around this
Earlier coverage that leads up to this article, and what followed. Lines connect each piece to the closest one after it, converging here.
More from TechCrunch AI
© TechCrunch AIMarket & Regulationbusiness
Crusoe cancels $1.25B Boom turbine deal
The collapse of Crusoe’s $1.25 billion order for Boom Supersonic’s stationary turbines exposes the fragility of AI infrastructure financing. While Crusoe raised $3.9 billion, it pivoted away from on-site gas generation, opting instead for grid power and diverse energy mixes. This signals that even well-funded data center operators are prioritizing flexibility over massive, long-term capital commitments to specialized hardware. Boom’s pivot to sell jet engines as power plants was a bold bet on AI energy needs, but losing its anchor customer suggests the market is more cautious than anticipated.
TechCrunch AI
© TechCrunch AIMore in Market & Regulation
© Lev SelectorMarket & Regulationbusiness
OpenAI Eyes $1.5 Trillion Valuation
Reports indicate OpenAI is targeting a valuation of $1.5 trillion in its next funding round, reflecting massive investor confidence.
Lev Selector
© Lev SelectorMarket & Regulationbusiness
